HeartSciences Granted U.S Patent for ECG Assessment of Heart Diastolic Function Using Artificial Intelligence
September 20 2022 - 8:30AM
Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:
HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical
technology company focused on applying innovative AI-based
technology to an ECG (also known as an EKG) to significantly expand
and improve an ECG’s clinical usefulness by detecting cardiac
dysfunction, today announced that it has been granted a patent from
the United States Patent and Trademark Office (USPTO) for ECG
quantification of echocardiographic measures of diastolic function
of the heart using AI methods.
Diastolic dysfunction (impaired cardiac
relaxation) is an important indicator of overall heart health as it
is impaired by all of the common pathological processes of heart
disease and is a sensitive indicator of cardiovascular dysfunction.
Diastolic dysfunction is recognized as one of the earliest signs of
heart disease and typical onset occurs when a patient is still
asymptomatic.
Today, diastolic function of the heart must be
assessed in a specialist cardiology environment typically using
echocardiography-based imaging. Historically, ECGs have had
limited, if any, role in the evaluation of cardiac dysfunction and,
therefore, the ability to assess cardiac diastolic function using
an ECG would make it a far more valuable cardiac screening tool
particularly in frontline or point-of-care clinical
settings.
HeartSciences’ first device, the
MyoVista® Wavelet ECG (wavECG™) leverages AI machine learning
to detect cardiac dysfunction that cannot be diagnosed by current
conventional ECGs. Its first algorithm is designed to
provide diagnostic information related to impaired cardiac
relaxation associated with diastolic dysfunction as well as all
conventional ECG information in a single test.
Andrew Simpson, Chief Executive Officer of
HeartSciences, stated, “The ECG is a ubiquitous, relatively
low-cost, simple and quick test that can be performed in a wide
range of clinical settings by a non-specialist clinician or
clinical aide. One of the most significant needs in healthcare is
the ability to detect cardiac dysfunction early. Adding
diagnostic information related to cardiac dysfunction to an ECG
would not only make it a far more valuable cardiac screening tool,
but also addresses a significant unmet need in the market with an
estimated 100 million plus ECG tests performed annually in the USA
alone.”
“A growing body of published ECG research
demonstrates that ECGs can have far greater clinical value and the
grant of this patent reinforces our belief the HeartSciences is
positioned at the forefront of what is expected to be a new era for
ECGs. This latest patent is an important extension of
our IP portfolio - providing significant prospective value for the
company,” concluded Mr. Simpson.
Mr. Mark Hilz, Chief Operating Officer of
HeartSciences, commented, “We are committed to patent and
intellectual property protection related to our research and
development efforts focused on expanding ECG clinical capabilities.
We believe patent and IP protection is essential, while pursuing
novel advancements for ECGs, and are proud to be awarded this
valuable patent by the USPTO.”
The Company to date has been granted eight patents
in the U.S. (including the one announced in this press release),
bringing the Company’s total granted patents, including
international, to eighteen as of the date of this press release.
The Company has also received allowances of further applications by
the European Patent Office and Israel with several additional
pending patent applications in multiple international jurisdictions
including Brazil, Canada, India, South Korea, Mexico, and the
United Arab Emirates.
About HeartSciences
Heart Test Laboratories, Inc. d/b/a HeartSciences
is medical technology company focused on applying innovative
AI-based technology to an ECG (also known as an EKG) to expand and
improve an ECG’s clinical usefulness. The Company’s objective is to
make an ECG a far more valuable cardiac screening tool,
particularly in frontline or point-of-care clinical settings.
HeartSciences’ first product candidate for FDA clearance, the
MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is
also designed to provide diagnostic information related to cardiac
dysfunction which has traditionally only been available through the
use of cardiac imaging. The MyoVista also provides conventional ECG
information in the same test. The business model, which involves
the use of the MyoVista device and consumables for each test, is
expected to be “razor-razorblade” as the electrodes used with the
MyoVista are proprietary to HeartSciences, and new electrodes are
required for every test performed.
For more information, please visit:
https://www. heartsciences.com.
Safe Harbor Statement
This announcement contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are made under the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995
and are relating to the Company's future financial and operating
performance. All statements, other than statements of historical
facts, included herein are "forward-looking statements" including,
among other things, statements about HeartSciences’ beliefs and
expectations. These statements are based on current expectations,
assumptions and uncertainties involving judgments about, among
other things, future economic, competitive and market conditions
and future business decisions, all of which are difficult or
impossible to predict accurately and many of which are beyond the
Company's control. The expectations reflected in these
forward-looking statements involve significant assumptions, risks
and uncertainties, and these expectations may prove to be
incorrect. Investors should not place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. Potential risks and uncertainties include, but are
not limited to, risks discussed in HeartSciences’ filings with the
U.S. Securities and Exchange Commission at www.sec.gov. Other than
as required under the securities laws, the Company does not assume
a duty to update these forward-looking statements.
For investor and media inquiries, please
contact:
Investor Relations:
Crescendo Communications, LLC
Phone: (212) 671-1021
Email: HSCS@crescendo-ir.com
Company:Gene GephartPhone: +1-737-414-9213
(US)Email: investorrelations@heartsciences.com
Heart Test Laboratories (NASDAQ:HSCS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Heart Test Laboratories (NASDAQ:HSCS)
Historical Stock Chart
From Sep 2023 to Sep 2024